We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| TScan Therapeutics Inc | NASDAQ:TCRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.81 | 7.97 | 9.42 | 0 | 09:16:51 |
From May 2023 to May 2024
By Chris Wack
TScan Therapeutics said Tuesday that the U.S. Food and Drug Administration has cleared its investigational new drug application for TSC-203-A0201, a TCR-T targeting preferentially expressed antigen in melanoma.
The clinical-stage biopharmaceutical company said TSC-203-A0201 is the fourth TCR-T cleared for clinical development in the company's solid tumor program.
TScan said it is on-track to treat the first patient with a TScan TCR-T and report preliminary data by the end of 2023.
TScan shares were up 8% to $2.37 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 29, 2023 07:47 ET (11:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year TScan Therapeutics Chart |
1 Month TScan Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
